Resistance mechanisms of tumour cells to EGFR inhibitors - PubMed (original) (raw)

Review

Resistance mechanisms of tumour cells to EGFR inhibitors

F Morgillo et al. Clin Transl Oncol. 2009 May.

Abstract

In spite of the overexpression and efficient inhibition of epidermal growth factor receptor (EGFR), resistance to EGFR inhibitors, monoclonal antibodies and tyrosine kinase inhibitors may occur. Understanding the molecular mechanisms affecting cancer cell sensitivity or resistance to EGFR inhibitors may be of help in deciding on treatment and in new translational studies. This review will focus on the most relevant mechanisms contributing to the acquisition of sensitivity/resistance to EGFR inhibitors.

PubMed Disclaimer

References

    1. Cancer Res. 2002 Oct 15;62(20):5749-54 - PubMed
    1. Cancer Res. 2002 Jan 1;62(1):200-7 - PubMed
    1. Clin Cancer Res. 2004 May 1;10(9):3216-24 - PubMed
    1. Curr Opin Oncol. 2005 Mar;17(2):118-22 - PubMed
    1. J Clin Oncol. 2005 Sep 1;23(25):5900-9 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources